drugset / Trial / NCT06885281
A Study of ZL-1310 in Participants With Selected Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Timeline
- Start
- 2025-05-12
- Primary completion
- 2027-08
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZL-1310 | Other / unclassified | 1.6 mg/kg | Intravenous |